Remote digital monitoring of generalized myasthenia gravis with the MyoSense 360 device

Trial details

Who runs it

Ad scientiam

Trial code

NCT07323316

Record updated

5 November 2026

Original description

The purpose of the HARMONY 360 investigation is to explore the feasibility of using MyoSense 360 digital measures to develop models capable of detecting clinically meaningful changes in generalized Myasthenia Gravis (gMG) trajectory over 12 months under real-world conditions. Its main objective is not yet to demonstrate the final conformity of the device (exploratory study under article 82), but to collect preliminary data of safety and clinical performance that will help to refine the final product and inform the subsequent pivotal study.Read full original descriptionShow less

Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360

The purpose of the HARMONY 360 investigation is to explore the feasibility of using MyoSense 360 digital measures to develop models capable of detecting clinically meaningful changes in generalized Myasthenia Gravis (gMG) trajectory over 12 months under real-world conditions. Its main objective is not yet to demonstrate the final conformity of the device (exploratory study under article 82), but to collect preliminary data of safety and clinical performance that will help to refine the final product and inform the subsequent pivotal study.

The primary objective focuses on developing models to detect disease trajectory changes defined by the clinically significant +/- 2 points MG-ADL threshold. Secondary objectives include assessing usability, adherence, and the feasibility of models for worsening/exacerbation prediction. Finally, risks and anticipated Adverse Device Effects (ADEs) associated with the device use will be monitored continuously throughout the investigation. Consistent with its Proof of Concept stage, the study defines no claims of clinical performance, effectiveness or safety.

Inclusion: Age ≥ 18 years at screening; Patients with gMG diagnosis confirmed by the investigator based at least on one of the following:; Positive antibody testing for ACHR or MuSK antibodies; or,; LRP-4 antibodies or seronegative patients with additional positive single fiber examination; or,; Abnormal single-fiber EMG (SFEMG) jitter in at least one clinically weak muscle; or,; Objective evidence of improvement of clinical gMG symptoms following treatment with oral AChEI or positive pyridostigmine or neostigmine or edrophonium test; MGFA Class IIa to IVb; Having read the information sheet and signed the informed consent form; Owning and able to use a personal smartphone which software version is above 16 for iOS and 8 for Android included; Able to read languages in which the mobile application is available and able to understand pictograms (MyoSense 360 is available in local official languages); Able to use an activity monitor (per Actigraph LEAP activity monitor wearability criteria; see vendor guidance); For France only, affiliated with or benefiting from a social security system.

Exclusion: Current drugs or/and alcohol abuse that could influence performance on the tests, as judged by the investigator; Participant has participated in another interventional clinical study within 30 days prior to screening or who are currently enrolled in another study that, in the - Investigator's opinion, could interfere with their full participation in this study or confound the assessment of the subject or study outcomes; For France only, participant who has received more than €6,000 in compensation over the past 12 months for participating in human research, clinical trials, clinical investigations or performance studies; Known medical or psychological condition(s) or risk factor(s) that, as judged by the investigator, might interfere with the subject's full participation in the study, pose any additional risk for the subject, or confound the assessment of the subject or outcome of the study; Person under guardianship or curatorship.

ClinicalTrials.gov NCT07323316